Hämato-Onkologie im Medicum

The department of Hämato‑Onkologie im Medicum focuses on Neoplasms, specifically hormone‑receptor‑positive, HER2‑negative early breast cancer. Current studies aim to evaluate a chemotherapy‑sparing approach by comparing a ribociclib‑based adjuvant regimen with the traditional sequence that includes chemotherapy, seeking to maintain disease‑free survival while reducing treatment burden.

• HR+ HER2- early breast cancer
• Chemotherapy de‑escalation
• Ribociclib combined with endocrine therapy
• Assessment of invasive breast cancer‑free survival

By exploring non‑inferior outcomes, the trial supports personalized treatment strategies that may limit exposure to cytotoxic agents.

Research at the site also addresses primary high‑risk lobular breast cancer, investigating a targeted combination of a AKT inhibitor with endocrine therapy. The study examines whether adding the investigational agent can achieve complete cell‑cycle arrest, potentially enhancing tumor control without additional chemotherapy.

• High‑risk lobular breast cancer
• Capivasertib plus fulvestrant therapy
• Evaluation of complete cell cycle arrest
• Improved response in neoadjuvant setting

This work aims to refine treatment options for patients with aggressive lobular disease, emphasizing targeted therapy over conventional chemotherapy.